ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MED vs KOF // GROSS PROFIT MARGIN

MEDIFAST INC (NYSE) VS. Coca Cola Femsa S.A.B. de C.V. American (NYSE) • 15-METRIC TALLY: MED 3 — KOF 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MED VS. KOF) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MED KOF SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 71.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -10.20% 9.90% -20.10 KOF /roic <GO>
EV/EBITDA & P/E Valuation — 21.0x — TIE /valuation <GO>
Free Cash Flow Yield 0.91% 2.21% -1.30 KOF /fcf-yield <GO>
Operating Margin -3.70% 13.90% -17.60 KOF /operating-margins <GO>
Net Profit Margin -4.90% 10.90% -15.80 KOF /net-margins <GO>
Revenue Growth (YoY) -36.00% 3.30% -39.30 KOF /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.14% 0.00% +0.14 MED /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.71 3.74 +0.97 MED /balance-sheet <GO>
Piotroski F-Score Quality 5/9 7/9 -2.00 KOF /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.7 54.2 +2.50 MED /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.88 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 30.5x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $137.1M $194.12B -$193.98B KOF /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MED REV KOF REV MED GROSS % KOF GROSS % MED FCF KOF FCF
FY 2025 $385.8M — 71.3% — $1.2M —
FY 2024 $602.5M — 73.8% — $17.0M —
FY 2023 $1.07B — — — $147.7M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MED // BETA —
KOF // BETA 0.88